4425-56-3

Basic information

• Product Name: 5-Cyanouracil
• Synonyms: 5-CYANOURACIL;2,4-DIHYDROXYPYRIMIDINE-5-CARBONITRILE;5-Pyrimidinecarbonitrile, 1,2,3,4-tetrahydro-2,4-dioxo- (6CI,7CI,8CI,9CI);5-CYANO-2,4-DIHYDROXYPYRIMIDINE;2,4-Dioxo-1H-pyrimidine-5-carbonitrile;2,4-Dihydroxy-5-pyrimidinecarbonitrile;2,4-diketo-1H-pyrimidine-5-carbonitrile;2,4(1H,3H)-Pyrimidinedione, 5-cyano-
• CAS NO: 4425-56-3
• Molecular Formula: C₅H₃N₃O₂
• Molecular Weight: 137.1
• Product Categories: PYRIMIDINE;Pyrazines, Pyrimidines & Pyridazines;Pyrazines, Pyrimidines & Pyridazines
• Mol File: 4425-56-3.mol
• Article Data: 8

Chemical Properties

• Melting Point: 295 °C (decomp)
• Boiling Point: 524.836 °C at 760 mmHg
• Flash Point: 271.211 °C
• Appearance: /
• Density: 1.708 g/cm³
• Vapor Pressure: 1.24E-11mmHg at 25°C
• Refractive Index: 1.59
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 5.76±0.10(Predicted)
• CAS DataBase Reference: 5-Cyanouracil(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Cyanouracil(4425-56-3)
• EPA Substance Registry System: 5-Cyanouracil(4425-56-3)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 4425-56-3(Hazardous Substances Data)

Usage

General Description

5-Cyanouracil is a chemical compound belonging to a class of molecules known as pyrimidines which are key components of DNA and RNA. This derivative of uracil, a common base in RNA, is distinguished by the addition of a cyano group at its 5th position. Wealth of research has been done on this substance for its potential implications in the field of medicinal chemistry, with specific reference to anti-cancer activity. Its synthesis often involves reactions such as nucleophilic substitution or condensation in order to add the cyano group to the uracil base. As with any chemical, appropriate care should be taken when handling 5-Cyanouracil given potential health and safety risks.

InChI:InChI=1/C5H3N3O2/c6-1-3-2-7-5(10)8-4(3)9/h2H,(H2,7,8,9,10)

Upstream product

• 1187-34-4 α-Cyano-β-ethoxy-N-(ethoxycarbonyl)acrylamide 
• 85690-57-9 methyl (E)-2-cyano-3-ureido-2-propenoate 
• 61679-83-2 ethyl ureidomethylene cyanoacetate 
• 16462-28-5 5-cyanocytosine 
• 1187-34-4 α-cyano-β-ethoxy-N-ethoxycarbonylacrylamide 
• 162129-62-6 ethyl (E)-2-cyano-3-ureido-2-propenoate 

Downstream Products

• 3177-24-0 2,4-dichloropyrimidine-5-carbonitrile 
• 1350660-71-7 5-(3-p-tolyl-1,2,4-oxadiazol-5-yl)pyrimidine-2,4(1H,3H)-dione 
• 66-22-8 uracil 
• 51-21-8 5-fluorouracil 
• 23945-44-0 2,4-dihydroxypyrimidine-5-carboxylic acid 
• 65906-82-3 5-cyano-6-ethoxy-5-fluoro-5,6-dihydrouracil 
• 1350660-73-9 5-(3-(4-bromophenyl)-1,2,4-oxadiazol-5-yl)pyrimidine-2,4(1H, 3H)-dione 
• 1350660-75-1 5-(3-(4-methoxyphenyl)-1,2,4-oxadiazol-5-yl)pyrimidine-2,4(1H,3H)-dione 
• 1350660-72-8 5-(3-(4-chlorophenyl)-1,2,4-oxadiazol-5-yl)pyrimidine-2,4(1H,3H)-dione 

Relevant articles and documents

CYCLIZATION DICHOTOMY OF ESTERS OF 3-UREIDO-2-CYANO-2-PROPENOIC AND 3-UREIDO-2-ACYL-2-PROPENOIC ACIDS

The preparation of E and Z isomers of 3-ureido-2-cyano-2-propenoates Ia-Id and their base-catalyzed isomerization and cyclization to 5-carboxycytosine derivatives IIa-IIf and 5-cyanouracil derivatives IIIa and IIIb is described.Also described is the preparation of 3-ureido-2-acyl-2-propenoates Va-Vd and their base-catalyzed cyclization to 5-carboxy-2(1H)-pyrimidone derivatives VIa-VIc and 5-acyluracils VIIa-VIIc.

Pyrimidine derivatives useful as inhibitors of PKC-theta

Disclosed are novel compounds of formula (I): wherein X, Y, R1, R2 and R3 are as defined herein, which are useful as inhibitors of PKC-theta and are thus useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of PKC-theta, including immunological disorders and type II diabetes. This invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.

5-Fluorouracil derivatives

Novel compounds comprising 5-fluorouracil or 5-fluorouridine covalently linked to 5-ethynyluracil, 5-ethynyluridine or 5-propynyluracil and pharmaceutical compositions comprising such compounds are disclosed.